Board Member
Neurocrine Biosciences Inc (NBIX)Equibles does not estimate personal net worth.
Get an email with a short summary when Neurocrine Biosciences Inc publishes a filing, an earnings call transcript or a press release.
Get NBIX alertsKevin Gorman is recorded as Board Member at Neurocrine Biosciences Inc (NBIX) since January 1, 2008 and CEO at Neurocrine Biosciences Inc (NBIX). The proxy statement of Neurocrine Biosciences Inc reports total compensation of $16,018,637 for Kevin Gorman in fiscal 2024, including a base salary of $779,357. Disclosed compensation is on record for 8 fiscal years. Kevin Gorman has spoken on 18 earnings calls and 1 other investor event across 1 company, most recently for Neurocrine Biosciences Inc on May 26, 2026. Neurocrine Biosciences Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Neurocrine Biosciences Inc includes Kyle Gano, Ph.D. (CEO and Board Member), Kyle W. Gano (CEO and Board Member), Matthew C. Abernethy (CFO) and 7 others.
“We will be making forward-looking statements, and part of that will be whether you want the Spurs or the Knicks to win. So we will have an FLS for that. But, yeah, we have a lot going on at Neurocrin.”
“We have a lot to go over this morning, but I'd like to start out with a statement that we have no information to share on either Luvadaxistat or NBI-'568 or M4 agonist.”
“We've had a remarkable week and it's only Wednesday morning. We've submitted two NDAs on crinecerfont and received an FDA approval for a new offering of INGREZZA.”
“I said the same thing about 2022, and it was great. I said there were very few years you get like 2022, and we then had one of those years in 2023. Both of those years were not without their ups and downs, but on the whole, the business performed exceptionally well.”
“I think everyone else who’s going to be talking on the call will, and as always, we just want to spend as much time with your questions as possible.”
2008-01-01–present
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
2008-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Neurocrine Biosciences Inc (NBIX) | CEO | $779,357 | $16,018,637 |
| 2023 | Neurocrine Biosciences Inc (NBIX) | CEO | $946,000 | $15,750,812 |
| 2022 | Neurocrine Biosciences Inc (NBIX) | CEO | $860,000 | $11,902,527 |
| 2021 | Neurocrine Biosciences Inc (NBIX) | CEO | $825,000 | $14,081,412 |
| 2020 | Neurocrine Biosciences Inc (NBIX) | CEO | $775,000 | $13,880,632 |
| 2019 | Neurocrine Biosciences Inc (NBIX) | CEO | $725,000 | $9,450,826 |
| 2018 | Neurocrine Biosciences Inc (NBIX) | CEO | $675,000 | $8,632,979 |
| 2017 | Neurocrine Biosciences Inc (NBIX) | CEO | $640,000 | $7,556,374 |
